HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
Abstract Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, neratinib, tucatinib, and pyrotinib. Thes...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Nature Portfolio
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/5bfaa35b932a447fac6aa414a235208c |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|